BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) announced today that researchers have correlated Tß4 levels with the clinical course of patients with hepatitis B virus-related liver failure. It was reported that serum thymosin ß4 levels were significantly lower in patients with chronic hepatitis B infection and that the magnitude of the reduction of thymosin ß4 was closely related to the severity of the hepatic injury and to patient death. Since patients with higher Tß4 levels survived the disease, changes in Tß4 values could reflect outcome in some liver failure patients.
